Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$70.30

1.73 (2.52%)

, NBIX

Neurocrine

$51.26

0.99 (1.97%)

05:38
10/06/16
10/06
05:38
10/06/16
05:38

Alnylam downgraded to Equal Weight from Overweight at Barclays

Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.

ALNY

Alnylam

$70.30

1.73 (2.52%)

NBIX

Neurocrine

$51.26

0.99 (1.97%)

PRTA

Prothena

$62.92

1.11 (1.80%)

INCY

Incyte

$95.69

1.52 (1.61%)

  • 07

    Oct

  • 07

    Oct

  • 14

    Oct

  • 06

    Nov

ALNY Alnylam
$70.30

1.73 (2.52%)

09/15/16
FBRC
09/15/16
INITIATION
Target $82
FBRC
Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
08/22/16
WEDB
08/22/16
NO CHANGE
WEDB
Intellia Therapeutics data positive, says Wedbush
Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.
09/28/16
JANY
09/28/16
INITIATION
Target $74
JANY
Neutral
Alnylam initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated Alnylam with a Neutral and a $74 fair value estimate. The analyst is not confident about the outcome for the pivotal study for patisiran in transthyretin familial amyloid neuropathy, expected in about 12 months, and give patisiran a 50% chance of success.
NBIX Neurocrine
$51.26

0.99 (1.97%)

06/06/16
BMOC
06/06/16
NO CHANGE
BMOC
Neurocrine price target raised to $66 from $57 at BMO Capital
BMO Capital raised its price target on Neutrocirne (NBIX) as it believes that the company's elagolix drug has a positive read through from data recently presented by AbbVie (ABBV). .
09/23/16
LEER
09/23/16
NO CHANGE
LEER
Outperform
Positive data paves way for Teva SD-809 indication, says Leerink
Leerink analyst Jason Gerberry says the AIM-TD study readout clinically de-risks Teva's (TEVA) SD-809 opportunity for tardive dyskinesia, with the investor focus shifting to market size and competitive differentiation versus Neurocrine's (NBIX) valbenazine. The analyst believes Teva's SD-809 is well positioned to compete against valbenazine with an equally efficacious and well tolerated drug. Further, he expects Teva to exit 2017 with a broader label. Gerberry reiterates an Outperform rating on Teva's shares.
10/04/16
LEER
10/04/16
INITIATION
Target $70
LEER
Outperform
Neurocrine reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of Neurocrine with an Outperform rating and $70 price target.
06/29/16
HCWC
06/29/16
INITIATION
Target $80
HCWC
Buy
Neurocrine initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started Neurocrine Biosciences with a Buy rating and $80 price target.
PRTA Prothena
$62.92

1.11 (1.80%)

06/10/16
RBCM
06/10/16
NO CHANGE
RBCM
Prothena data positive, says RBC Capital
RBc Capital believes that the Phase I data for Prothena's antibody program, '003, was positive. The firm thinks the treatment "could be a new psoriasis drug or go after other big inflammatory markets." The firm expects '003 to begin to get attention from investors, and it views the product as "somewhat de-risked." RBC keeps an Outperform rating on the shares.
09/27/16
RBCM
09/27/16
NO CHANGE
RBCM
Prothena CEO change 'neutral, natural, and positive' says RBC Capital
Afte Prothena announced its CEO was taking a medical leave and that it was elevating its COO, Gene Kinney, to interim CEO, RBC Capital analyst Michael Yee says "this a a neutral and natural positive development." Yee reports that Kinney " has been generally in charge of and overseen the R&D and clinical development of their 3 lead programs and involved in leading discussions with the FDA." The analyst believes that the company had previously been planning for succession and that investors should not be surprised by this development, as they knew that the CEO had health problems. Yee keeps an Outperform rating on the shares.
08/03/16
LTCO
08/03/16
NO CHANGE
Target $80
LTCO
Buy
Prothena price target raised to $80 from $77 at Ladenburg
Ladenburg Thalmann analyst Robert Hazlett said the recently released clinical data from the Phase 1/2 study of NEOD001 continue to point to promising organ responses that do not appear to be related to prior plasma cell directed therapy. Noting there are catalysts upcoming for NEOD001, PRX002 and PRX003, the analyst raised his price target on the stock to $80, adding that he assigns a 70% probability of Prothena operating independently and a 30% probability to a takeover.
09/27/16
UBSW
09/27/16
NO CHANGE
Target $73
UBSW
Buy
Prothena management has continuity during CEO leave of absence, says UBS
UBS analyst Jeffrey Hung noted that Prothena's COO Gene Kinney will lead the company while its CEO, Dale Schenk, is on a medical leave of absence. Hung notes that the NEOD001 strategy is already largely in place and he believes the Board's confidence in Kinney, combined with his recent promotion, points to the potential for a natural succession. The analyst keeps a Buy rating and $73 price target on Prothena shares.
INCY Incyte
$95.69

1.52 (1.61%)

08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
09/29/16
RAJA
09/29/16
UPGRADE
Target $115
RAJA
Outperform
Incyte upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Reni Benjamin upgraded Incyte to Outperform with a $115 price target following the release of an abstract showcasing "positive" long-term follow-up results for epacadostat in melanoma. Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab, Benjamin tells investors in a research note.
09/29/16
09/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. eBay (EBAY) upgraded to Buy from Hold at Deutsche Bank with analyst Ross Sandler saying eBay is likely to outperform Internet peers over the next two years now that its re-platforming is in the latter stages. 2. BlackBerry (BBRY) upgraded to Neutral from Underperform at Macquarie with analyst Gus Papageorgiou saying he expects operations to stabilize and profitability to return next year. 3. Endo (ENDP) upgraded to Outperform from Market Perform at Northland. 4. Rex Energy (REXX) upgraded to Hold from Sell at Stifel with analyst Michael Scialla saying the production cut may not actually occur, but he believes that other factors, along with positive commentary from OPEC, "appears to be building an oil price floor of $40." 5. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin saying Epacadostat plus pembrolizumab, should ;the results be confirmed in the ongoing Phase III study, could effectively compete with ipilimumab and nivolumab. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/16
09/21/16
NO CHANGE

RBC identifies top biotech takeover candidates
RBC Capital identified the following names as its top potential takeover candidates in the biotech space: ARIAD (ARIA), Spark Therapeutics (ONCE), BioMarin (BMRN), Aerie Pharmaceuticals (AERI), Intra-Cellular (ITCI), TESARO (TSRO), Incyte (INCY), Sarepta (SRPT), and Puma Biotechnology (PBYI). The firm thinks that investors are underestimating the positive impact that M&A will have on biotech stock prices.

TODAY'S FREE FLY STORIES

SYRS

Syros Pharmaceuticals

$16.86

-0.32 (-1.86%)

08:09
06/23/17
06/23
08:09
06/23/17
08:09
Hot Stocks
Syros Pharmaceuticals presents preclinical data on SY-1425 »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRY

BlackBerry

$11.06

0.41 (3.85%)

08:09
06/23/17
06/23
08:09
06/23/17
08:09
Hot Stocks
BlackBerry says won central bank of France as new customer »

Says cyber security…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

EA

Electronic Arts

$112.62

-0.55 (-0.49%)

08:07
06/23/17
06/23
08:07
06/23/17
08:07
Recommendations
Electronic Arts analyst commentary  »

Electronic Arts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$126.23

2.65 (2.14%)

08:05
06/23/17
06/23
08:05
06/23/17
08:05
Hot Stocks
Alexion announces positive CHMP opinion for Soliris »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ALGN

Align Technology

$149.69

0.27 (0.18%)

08:04
06/23/17
06/23
08:04
06/23/17
08:04
Recommendations
Align Technology analyst commentary  »

Align Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

TRMK

Trustmark

$31.67

-0.53 (-1.65%)

08:04
06/23/17
06/23
08:04
06/23/17
08:04
Downgrade
Trustmark rating change  »

Trustmark downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVEO

AVEO Oncology

$0.73

0.0281 (4.02%)

08:03
06/23/17
06/23
08:03
06/23/17
08:03
Hot Stocks
AVEO Oncology reports positive CHMP opinion for tivozanib as RCC treatment »

AVEO Oncolog announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$170.68

0.5 (0.29%)

, HUM

Humana

$237.00

0.79 (0.33%)

08:03
06/23/17
06/23
08:03
06/23/17
08:03
Recommendations
Cigna, Humana, Aetna, WellCare, Anthem, Health Net, Centene, Molina Healthcare, UnitedHealth analyst commentary  »

Jefferies says healthcare…

CI

Cigna

$170.68

0.5 (0.29%)

HUM

Humana

$237.00

0.79 (0.33%)

AET

Aetna

$152.98

0.88 (0.58%)

WCG

WellCare

$183.60

6.06 (3.41%)

ANTM

Anthem

$193.36

1.29 (0.67%)

HNT

Health Net

CNC

Centene

$83.00

2.88 (3.59%)

MOH

Molina Healthcare

$71.31

1.58 (2.27%)

UNH

UnitedHealth

$186.50

1.58 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

ZAYO

Zayo Group

$31.27

-0.54 (-1.70%)

08:03
06/23/17
06/23
08:03
06/23/17
08:03
Hot Stocks
Zayo Group selected by global webscale company for wavelength solution »

A global webscale company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSM

Williams-Sonoma

$47.18

0.48 (1.03%)

08:02
06/23/17
06/23
08:02
06/23/17
08:02
Hot Stocks
Williams-Sonoma to open expansive dual concept store in Seattle »

Williams Sonoma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRFT

Perficient

$17.55

0.15 (0.86%)

08:01
06/23/17
06/23
08:01
06/23/17
08:01
Hot Stocks
Perficient acquires Clarity Consulting in accretive deal »

Perficient announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

NSAT

Norsat

08:01
06/23/17
06/23
08:01
06/23/17
08:01
Hot Stocks
Norsat shareholders approve plan of arrangement with Hytera Communications »

Norsat announced that at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATB

Catabasis Pharmaceuticals

$1.30

-0.01 (-0.76%)

08:00
06/23/17
06/23
08:00
06/23/17
08:00
Hot Stocks
Catabasis Pharmaceuticals to present results from MoveDMD trial at PPMD »

Catabasis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

P

Pandora

$7.80

0.29 (3.86%)

08:00
06/23/17
06/23
08:00
06/23/17
08:00
Options
Pandora call buyer realizes 8% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BIIB

Biogen

$280.57

1.97 (0.71%)

, SSNLF

Samsung

08:00
06/23/17
06/23
08:00
06/23/17
08:00
Hot Stocks
Biogen's IMRALDI granted positive opinion by CHMP »

The Committee for…

BIIB

Biogen

$280.57

1.97 (0.71%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

08:00
06/23/17
06/23
08:00
06/23/17
08:00
General news
N.Y. FX Outlook: The dollar looks likely to remain on a neutral footing »

N.Y. FX Outlook: The…

FIT

Fitbit

$5.09

0.1 (2.00%)

07:59
06/23/17
06/23
07:59
06/23/17
07:59
Recommendations
Fitbit analyst commentary  »

Fitbit reorganization of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$32.66

-0.5 (-1.51%)

07:59
06/23/17
06/23
07:59
06/23/17
07:59
Technical Analysis
Technical View: Hain Celestial near 52-week low in pre-market, analyst actions »

The stock is down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

MEI

Methode Electronics

$40.10

1.45 (3.75%)

07:54
06/23/17
06/23
07:54
06/23/17
07:54
Recommendations
Methode Electronics analyst commentary  »

Baird remains a buyer of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HNHPF

Hon Hai Precision

, TOSYY

Toshiba, also use TOSBF

$17.39

0.085 (0.49%)

07:53
06/23/17
06/23
07:53
06/23/17
07:53
Periodicals
Foxconn's Gou still sees 50% chance of landing Toshiba chip unit, DigiTimes says »

Foxconn (HNHPF) Chairman…

HNHPF

Hon Hai Precision

TOSYY

Toshiba, also use TOSBF

$17.39

0.085 (0.49%)

TOSBF

Toshiba, also use TOSYY

$2.88

-0.01 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$35.36

0.48 (1.38%)

07:53
06/23/17
06/23
07:53
06/23/17
07:53
Hot Stocks
AstraZeneca announces positive CHMP opinion for Faslodex »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

V

Visa

$93.95

-0.59 (-0.62%)

07:52
06/23/17
06/23
07:52
06/23/17
07:52
Recommendations
Visa analyst commentary  »

Visa a good idea for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARA

Cara Therapeutics

$19.88

0.38 (1.95%)

07:51
06/23/17
06/23
07:51
06/23/17
07:51
Technical Analysis
Technical View: Cara Therapeutics at new 52-week high in pre-market »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jul

KMX

CarMax

$62.50

2.76 (4.62%)

07:51
06/23/17
06/23
07:51
06/23/17
07:51
Recommendations
CarMax analyst commentary  »

CarMax weakness on sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 30

    Jun

07:50
06/23/17
06/23
07:50
06/23/17
07:50
General news
Treasury Market Outlook: bonds are mixed while stocks are mostly lower »

Treasury Market Outlook:…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.